# AbbVie Inc (ABBV) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ABBV
## Company Profile
- Ticker: ABBV
- Exchange: NYSE
- Sector: Biopharma, Immunotherapy, CNS
- Location: United States
- Tags: Immunotherapy, Oncology, Immunology, CNS
## Stock Data
- Close: 246.2 USD
- Market cap: 380567173643.4 USD
- Last updated: 2026-08-05
## Business Overview
AbbVie is a large biopharmaceutical company with major franchises in immunology, aesthetics, neuroscience, and oncology. Its identity has evolved from a single-product legacy into a broader diversified growth story.
## Why The Stock Is Moving

As of Aug 5, 2026, ABBV closed up 0.98% at $246.20. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NYSE, AbbVie has a global commercial footprint with meaningful exposure to both developed and international markets. It sits firmly in large-cap biopharma.

## Business Model

AbbVie combines mature cash flow with pipeline reinvestment and lifecycle management. Investors focus on immunology growth, aesthetic product performance, patent runoff, and the replacement cycle across its core portfolio.

## Landscape Position

AbbVie is a mature large-cap biotech-like pharma with a strong commercial base and ongoing catalyst sensitivity. It is not binary, but pipeline, label, and patent developments still matter for valuation.

## Future Catalysts

- AbbVie’s key near-term catalysts are pivekimab sunirine’s BLA path, Rinvoq label-expansion opportunities, and continued Skyrizi momentum. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.

## Recent News
- No recent company news available.